Chronic hepatitis B infection in pregnancy

Table 2 Landmark study results of nucleos(t)ide analogues in hepatitis B virus infection and pregnancy

Ref.	Medication	Treatment timing	Major adverse events	% of transmission
				Treatment group	Control group
Han et al[14]	LdT 600 mg daily	20 to 32 wk	0%	0%	8%
van Zonneveld et al[15]	LAM 150 mg daily	34 wk	0%	12.5%	28%
Pan et al[19]	LdT 300 mg daily	23 wk	0%	0%	8.6%
Zhang et al[20]	LdT 600 mg daily or LAM 100 mg daily	28 wk	0%	0%	2.8%
Greenup et al[21]	TDF 300 mg daily	32 wk	0%	1.1%	20%

LAM: Lamivudine; LdT: Telbivudine; TDF: Tenofovir.